|Phase III||Treatment||Completed||any age||NCI||SWOG-8892|
EST-2388, RTOG-8817, INT-0099
I. Compare, in a multi-institutional Phase III setting, CR rate, time to treatment failure, overall survival, and patterns of recurrence among patients with Stage III/IV nonmetastatic carcinoma of the nasopharynx randomly assigned to treatment with radiotherapy alone vs. radiotherapy with concurrent cisplatin followed by cisplatin/fluorouracil. II. Compare the qualitative and quantitative toxicities of these two treatment regimens.
Histologically proven carcinoma of the nasopharynx No prior or concurrent adenocarcinoma Previously untreated Stage III/IV (M0) disease At least 1 bidimensionally measurable lesion required, with diagrams made of primary and nodal metastases by CT or MRI of nasopharynx, base of skull, and cervical/supraclavicular lymph node-bearing regions with 28 days of entry No lung, bone, or liver metastases by the following procedures: Chest x-ray within 42 days of entry Liver and bone scans (if alkaline phosphatase or SGOT is elevated or if clinically indicated) within 42 days of entry Examination of oral cavity, oropharynx, and larynx by a multimodal team required, including dental care analysis Concurrent registration on SWOG-8855 (flow cytometry protocol) allowed
Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy except for nonmelanomatous skin cancer outside the planned radiotherapy treatment volumes Surgery: No prior surgery to the primary site or nodes (except diagnostic) No resection following completion of protocol treatment except for the removal of persistent neck nodes
Age: Any age Performance status: SWOG 0-2 (Karnofsky 50-100%) Life expectancy: At least 6 months Hematopoietic: WBC at least 4,000 AGC at least 2,000 Platelets at least 100,000 Hepatic: Liver and bone scans required if alkaline phosphatase or SGOT are elevated Renal: Creatinine no more than 1.6 mg/dl OR Creatinine clearance at least 60 ml/min Other: No second malignancy within 5 years except: Basal cell skin cancer Carcinoma in situ of the cervix No pregnant or nursing women Effective contraception recommended for fertile women
270 patients will be randomized over 4.5-5.4 years.
Randomized study. Arm I: Radiotherapy. Irradiation of primary nasopharyngeal site and neck nodes using megavoltage equipment with energies of Co60 or greater. Arm II: Radiotherapy plus Concurrent Single-Agent Chemotherapy followed by 2-Drug Combination Chemotherapy. Radiotherapy as in Arm I; plus Cisplatin, CDDP, NSC-119875; followed by CDDP; Fluorouracil, 5-FU, NSC-19893.Published Results
Low WK, Toh ST, Wee J, et al.: Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 24 (12): 1904-9, 2006.[PUBMED Abstract]
Wee J, Tan EH, Tai BC, et al.: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23 (27): 6730-8, 2005.[PUBMED Abstract]
Bahl M, Siu LL, Pond GR, et al.: Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Int J Radiat Oncol Biol Phys 60 (4): 1127-36, 2004.[PUBMED Abstract]
Al-Sarraf M, Le Blanc M, Giri P, et al.: Superiority of five year survival with chemo-radiotherapy (CT-RT) vs radiotherapy in patients with locally advanced nosapharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388 phase III study: final report. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-905, 227a, 2001.
Al-Sarraf M, LeBlanc M, Giri PG, et al.: Chemo-radiotherapy(CT-RT) vs radiotherapy (RT) in patients (PTS) with locally advanced nasopharyngeal cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A1483, 385a, 1998.
Al-Sarraf M, LeBlanc M, Giri PG, et al.: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16 (4): 1310-7, 1998.[PUBMED Abstract]
Al-Sarraf M, LeBlanc M, Giri PG, et al.: Superiority of chemoradiotherapy (CT-RT) vs. radiotherapy (RT) in patients (pts) with locally advanced nasopharyngeal cancer (NPC). Preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study. [Abstract] Proceedings of the American Society of Clinical Oncology 15: A-882, 313a, 1996.
Al-Sarraf M, LeBlanc M, Giri PGS, et al.: Improved overall survival with chemo-radiotherapy (CT-RT) vs radiotherapy (RT) in patients with locally advanced nasopharyngeal cancer (NPC). Preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study. [Abstract] Proceedings of the International Conference on Head and Neck Cancer A240, 118, 1996.
Giri PG, Shankar LM, Al-Sarraf M, et al.: Improved survival with chemotherapy and radiation therapy versus radiation therapy alone in advanced nasopharyngeal cancer. Preliminary results of an intergroup randomized trial. INT 0099, SWOG 8892, RTOG 8817, ECOG 2388. [Abstract] Int J Radiat Oncol Biol Phys 36 (suppl 1): A-8, 162, 1996.
Trial Lead Organizations
Southwest Oncology Group
|Muhyi Al-Sarraf, MD, FRCPC, FACP, Protocol chair (Contact information may not be current)|
Eastern Cooperative Oncology Group
|George Adams, MD, Protocol chair (Contact information may not be current)|
Radiation Therapy Oncology Group
|Jay Cooper, MD, FACR, FACRO, Protocol chair (Contact information may not be current)|
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.